SGMO
Sangamo Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
consensus rating "Strong Buy"
Revenue Plunges
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SGMO
Sangamo Therapeutics, Inc.
A leading gene therapy company with a strong pipeline of treatments for rare genetic diseases
501 Canal Blvd., Richmond, California 94804
--
Sangamo Therapeutics, Inc., incorporated in Delaware on June 22, 1995, focuses on the development and commercialization of novel transcription factors for gene regulation and gene modification. The company is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of DNA-binding proteins for new therapeutic strategies for unmet medical needs. Currently, the company's scientific and business development efforts focus on gene regulation and modification of new zinc finger DNA-binding protein engineering. The company's strategy is to develop highly specific zinc finger protein nucleases and zinc finger protein transcription factors through early-stage clinical trials and strategic partnerships with biopharmaceutical companies to perform late-stage clinical trials and commercial development.
Company Financials
EPS
SGMO has released its 2024 Q4 earnings. EPS was reported at -0.11, versus the expected -0.07, missing expectations. The chart below visualizes how SGMO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SGMO has released its 2024 Q4 earnings report, with revenue of 7.55M, reflecting a YoY change of 269.78%, and net profit of -23.40M, showing a YoY change of 61.20%. The Sankey diagram below clearly presents SGMO’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
